A Case of Bilateral Breast Cancer with Severe Liver Dysfunction Caused by Simultaneous Liver Metastasis in which Chemotherapy could be Continued by Adjusting the Paclitaxel Dose-Reference-Cited by-同舟云学术

A Case of Bilateral Breast Cancer with Severe Liver Dysfunction Caused by Simultaneous Liver Metastasis in which Chemotherapy could be Continued by Adjusting the Paclitaxel Dose

Published:2021-04-10 Issue:4 Volume:47 Page:217-224
ISSN:1346-342X
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
language:en
Short-container-title:Jpn. J. Pharm. Health Care Sci.

Author:

Hashizume Junya¹,Matsumoto Megumi²,Yano Hiroshi²,Otsubo Ryota²,Fukushima Ayako²,Sato Kayoko¹,Nakagawa Hiroo¹,Harasawa Hitomi¹,Nakamura Tadahiro¹,Sasaki Hitoshi¹,Nagayasu Takeshi²,Kodama Yukinobu¹

Affiliation:

1. Department of Hospital Pharmacy, Nagasaki University Hospital

2. Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://www.jstage.jst.go.jp/article/jjphcs/47/4/47_217/_pdf

Reference23 articles.

1. 1）Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 2012, 366, 109-119.

2. 2）Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol, 2013, 14, 461-471.

3. 3）Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N Engl J Med, 2015, 372, 724-734.

4. 4）Swain SM, Miles D, Kim SB, Im YM, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, CLEOPATRA study group, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, Lancet Oncol, 2020, 21, 519-530.

5. 5）Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C, PhaseⅡ study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2―positive metastatic breast cancer, J Clin Oncol, 2015, 33, 442-447.